WO2022227987A1 - Dérivé hétérocyclique, son procédé de préparation et son utilisation - Google Patents

Dérivé hétérocyclique, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2022227987A1
WO2022227987A1 PCT/CN2022/083615 CN2022083615W WO2022227987A1 WO 2022227987 A1 WO2022227987 A1 WO 2022227987A1 CN 2022083615 W CN2022083615 W CN 2022083615W WO 2022227987 A1 WO2022227987 A1 WO 2022227987A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
cancer
alkyl
cycloalkyl
halogen
Prior art date
Application number
PCT/CN2022/083615
Other languages
English (en)
Chinese (zh)
Inventor
陈友喜
龚亮
向清
毛文涛
赵雯雯
赵伟峰
程超英
叶成
钱文建
陈磊
Original Assignee
浙江海正药业股份有限公司
上海昂睿医药技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江海正药业股份有限公司, 上海昂睿医药技术有限公司 filed Critical 浙江海正药业股份有限公司
Priority to CN202280006427.5A priority Critical patent/CN116157401A/zh
Publication of WO2022227987A1 publication Critical patent/WO2022227987A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • the present invention relates to a heterocyclic derivative, a preparation method thereof, a pharmaceutical composition containing the derivative and its use as a therapeutic agent, especially as a K-Ras GTPase inhibitor.
  • RAS represents a group of closely related monomeric globular proteins (21 kDa molecular weight) that have 189 amino acids and are associated with the plasma membrane and bind GDP or GTP. Under normal developmental or physiological conditions, RAS is activated upon receipt of growth factors and various other extracellular signals, and is responsible for regulating functions such as cell growth, survival, migration, and differentiation. RAS acts as a molecular switch, and the on/off state of RAS proteins is determined by nucleotide binding, with the active signaling conformation bound to GTP and the inactive conformation bound to GDP. When RAS contains bound GDP, it is in a dormant or quiescent or off state and is "inactive".
  • RAS When cells respond to exposure to certain growth-promoting stimuli, RAS is induced to convert bound GDP to GTP. With GTP bound, RAS is "on” and is able to interact with and activate other proteins (its “downstream targets”).
  • the RAS protein itself has a very low intrinsic ability to hydrolyze GTP back to GDP and thereby turn itself into the off state. Switching RAS off requires exogenous proteins called GTPases activating proteins (GAPs), which interact with RAS and greatly facilitate the conversion of GTP to GDP. Any mutation in RAS that affects its ability to interact with GAP or convert GTP back to GDP will result in prolonged activation of the protein and thus an extended signal to the cell that tells it to continue growing and split. So these signals allow cells to grow and divide, and overactive RAS signaling may ultimately lead to cancer.
  • RAS proteins contain a G domain responsible for the enzymatic activity of RAS, guanine nucleotide binding and hydrolysis (GTPase reaction). It also includes a C-terminal extension called the CAAX box, which can be post-translationally modified and target the protein to the membrane.
  • the G domain is approximately 21-25 kDa in size and contains a phosphate-binding loop (P-loop).
  • P-loop represents the pocket in the protein that binds nucleotides, and this is the rigid part of the domain with conserved amino acid residues necessary for nucleotide binding and hydrolysis (glycine 12, threo amino acid 26 and lysine 16).
  • the G domain also contains the so-called switch I region (residues 30-40) and switch II region (residues 60-76), both of which are the dynamic part of the protein as it switches between rest and load states capability is often denoted as a "spring loaded” mechanism.
  • the main interaction is the hydrogen bond formed by threonine-35 and glycine-60 with the ⁇ -phosphate of GTP, which allows switch I and switch II regions, respectively, to maintain their active conformations. After hydrolysis of GTP and release of phosphate, both relax to the inactive GDP conformation.
  • KRAS mutations are prevalent in the three most lethal cancer types in the United States: pancreatic cancer (95%), colorectal cancer (45%), and lung cancer (25%). KRAS mutations are also found in other cancer types including carcinoma, diffuse large B-cell lymphoma, rhabdomyosarcoma, cutaneous squamous cell carcinoma, cervical cancer, testicular germ cell carcinoma, etc. Rarely found ( ⁇ 2%).
  • NSCLC non-small cell lung cancer
  • KRAS G12C is the most common mutation, accounting for nearly half of all KRAS mutations, followed by G12V and G12D.
  • KRAS mutations in lung cancer including G12C
  • KRAS mutations frequently co-occur with certain co-mutations, such as STK11, KEAP1, and TP53, which cooperate with mutated RAS to transform cells into highly malignant and aggressive tumor cells.
  • KRas G12D inhibitors At present, there is fierce competition for clinical development of KRas G12D inhibitors at home and abroad. Among them, MRTX-1133, a KRas G12D inhibitor developed by Mirati Therapeutics Inc, has entered the preclinical stage for the treatment of colorectal tumors, non-small cell lung cancer and pancreatic cancer. . At present, there are a few patent applications for KRas G12D inhibitors published, including WO2021041671 of Mirati Therapeutics Inc. Although some progress has been made in the research and application of KRas G12D inhibitors, the room for improvement is still huge, and it is still necessary to continue the research and development of new KRas G12D inhibitors.
  • the object of the present invention is to provide a heterocyclic derivative represented by the general formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof:
  • Ring B is selected from aryl, heteroaryl or fused rings
  • Q is selected from N or CR a ;
  • Y is selected from a bond, -O- or -NRb ;
  • R a is selected from hydrogen atom, halogen, alkyl, alkoxy or cyano; wherein said alkyl or alkoxy is optionally further selected from one or more halogens, hydroxy, cyano, alkyl or alkane substituted by an oxy substituent;
  • R b is selected from a hydrogen atom or an alkyl group
  • R c is selected from hydrogen atom, halogen, cyano, alkyl or alkoxy; wherein said alkyl or alkoxy is optionally further selected by one or more of halogen, hydroxy, cyano, alkyl or alkoxy substituted by the substituent of oxy; R c is preferably halogen, more preferably fluorine or chlorine;
  • R 1 is selected from -L-cycloalkyl, -L-(6-membered to 9-membered) monocyclic heterocyclic group, -L-bicyclic heterocyclic group, -L-tricyclic heterocyclic group, -L-aryl, -L-heteroaryl or -L- fused ring; wherein said cycloalkyl, (6-9 membered) monocyclic heterocyclic group, bicyclic heterocyclic group, -tricyclic heterocyclic group, aryl,
  • L is each independently selected from a bond or a -C 1 -C 6 alkylene group, wherein said alkylene group is optionally further substituted with one or more R D ;
  • R D is each independently selected from a hydrogen atom, halogen, hydroxy or hydroxymethyl
  • R 2 are the same or different, each independently selected from hydrogen atom, halogen, hydroxyl, alkyl or alkoxy, preferably hydrogen atom or alkyl;
  • the radical or heteroaryl is optionally further selected from one or more of alkyl, halogen,
  • R 6 and R 7 together with the atoms to which they are attached form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) r , and the
  • R 8 , R 9 and R 10 are each independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclic group , aryl or heteroaryl are optionally further selected from one or more groups selected from hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl , substituted by a substituent of a carboxyl group or a carboxylate group;
  • n is selected from 0, 1, 2, 3 or 4;
  • n is selected from 0, 1, 2 or 3;
  • r 0, 1 or 2.
  • heterocyclic derivatives represented by the general formula (I), or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are represented by the general formula (II)
  • ring B, R 1 , R 2 , R 4 , R c , Y, m and n are as defined in general formula (I).
  • L is selected from a bond or a -C 1 -C 3 alkylene group, wherein said alkylene group is optionally further substituted by one or more R D ;
  • R D is each independently selected from a hydrogen atom, halogen, hydroxy or hydroxymethyl
  • two R D attached to the same carbon atom, together with the attached carbon atom form a cycloalkyl; preferably cyclopropyl.
  • L is selected from bond, -CH 2 -, -CH 2 CH 2 - or
  • the heterocyclic derivatives represented by the general formula (I), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein two R 3 are connected to them The atoms together form a 4-8 membered cycloalkyl or 4-8 membered heterocyclyl.
  • R 4 are the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen, an alkoxy group, an alkynyl group, a hydroxyl group, an amino group, a hydroxyalkyl group, a haloalkyl group or a haloalkoxy group;
  • Preferred is a hydrogen atom, methyl, fluorine, chlorine, hydroxy, amino, hydroxymethyl or ethynyl.
  • Ring B is selected from phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, indolyl, indazolyl, benzothiazolyl, tetralinyl,
  • Typical compounds of the present invention include, but are not limited to:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective dose of the compound of general formula (I) or (II) or its stereoisomer, tautomer or A pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or a combination thereof.
  • the present invention provides a method for inhibiting KRas G12D enzyme, wherein the method comprises administering to a patient a pharmaceutical composition containing an effective dose of general formula (I) or (II)
  • the compound or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, excipients or combinations thereof are administered to a patient a pharmaceutical composition containing an effective dose of general formula (I) or (II)
  • the compound or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, excipients or combinations thereof are examples of formula (I) or (II) The compound or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, excipients or combinations thereof.
  • the present invention also provides a compound of the general formula (I) or (II) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, which is prepared for the treatment by KRas Use in the medicine of the disease mediated by G12D mutation, wherein the disease mediated by KRas G12D mutation is selected from cancer, wherein the cancer is selected from cardiac myxoma, lung cancer, gastric cancer, colorectal cancer, rectal cancer, Pancreatic cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, chondrosarcoma, multiple myeloma, uterine cancer, cervical cancer, seminoma, malignant melanoma, skin squamous cell carcinoma, adrenal neuroblastoma , myeloid leukemia, acute lymphoblastic leukemia or glioblastoma, preferably pancreatic cancer, colorectal cancer, rectal cancer and lung cancer; wherein said
  • the present invention provides a compound of the general formula (I) or (II) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation Use in KRas G12D inhibitors.
  • Another aspect of the present invention relates to a method of preventing and/or treating a disease mediated by KRas G12D mutation, comprising administering to a patient a therapeutically effective dose of a compound of general formula (I) or (II) or its interconversion Isomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same.
  • the present invention also provides a compound of the general formula (I) or (II) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a compound for the treatment of cancer.
  • the cancer is selected from cardiac myxoma, lung cancer, gastric cancer, colorectal cancer, rectal cancer, pancreatic cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, chondrosarcoma, multiple myeloma , uterine cancer, cervical cancer, seminoma, malignant melanoma, cutaneous squamous cell carcinoma, adrenal neuroblastoma, myeloid leukemia, acute lymphoblastic leukemia or glioblastoma, preferably pancreatic cancer, colorectal cancer cancer, rectal cancer and lung cancer; wherein said lung cancer is preferably non-small cell lung cancer.
  • compositions of the present invention can be topical, oral, transdermal, rectal, vaginal, parenteral, intranasal, intrapulmonary, intraocular, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intradermal , intraperitoneal, subcutaneous, substratum corneum, or by inhalation.
  • Pharmaceutical compositions containing the active ingredient may be in a form suitable for oral administration, such as tablets, dragees, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or Elixirs. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients suitable for the manufacture of tablets.
  • the formulations of the present invention are suitably presented in unit dosage form, and such formulations may be prepared by any method well known in the art of pharmacy.
  • the amount of active ingredient that can be combined with carrier materials to produce a single dosage form can vary depending upon the host treated and the particular mode of administration.
  • the amount of active ingredient which, in combination with a carrier material, can produce a single dosage form generally refers to that amount of compound which produces a therapeutic effect.
  • Dosage forms for topical or transdermal administration of the compounds of this invention may include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and it can be mixed with any preservatives, buffers or propellants that may be required.
  • the compounds of the present invention When the compounds of the present invention are administered in pharmaceutical form to humans and animals, the compounds may be provided alone or in a pharmaceutical composition containing in combination with a pharmaceutically acceptable carrier active ingredient, for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of the active ingredient.
  • a pharmaceutically acceptable carrier active ingredient for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of the active ingredient.
  • Examples of pharmaceutically acceptable carriers include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and derivatives thereof such as carboxylate (4) powdered gum tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and Suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol , mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) seaweed (16) pyrogen-free water; (17) isotonic saline; (18) Ring
  • antioxidants examples include, but are not limited to: (1) water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; ( 2) Oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.
  • water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like
  • Oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (B
  • Solid dosage forms may include one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or the following Any one of: (1) fillers or bulking agents, such as starch, lactose, sucrose, glucose, mannitol and/or silicic acid; (2) binders, such as carboxymethyl cellulose, alginate, Gelatin, polyvinylpyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) dissolution retarders, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) humectants, such as cetyl alcohol and glycerol monostearate; (8)
  • Liquid dosage forms can include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzene Methanol, benzyl benzoate, propylene glycol, 1,3-butanediol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerin, tetrahydrofuran methanol, polyethylene Diols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as water or other solvents
  • solubilizers and emulsifiers such as ethanol
  • Suspensions in addition to the active compounds, may also contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum hydroxide oxide, bentonite, agar-agar and tragacanth and mixtures thereof.
  • suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum hydroxide oxide, bentonite, agar-agar and tragacanth and mixtures thereof.
  • Ointments, pastes, creams and gels can contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, poly Ethylene glycol, polysiloxane, bentonite, silicic acid, talc and zinc oxide or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, poly Ethylene glycol, polysiloxane, bentonite, silicic acid, talc and zinc oxide or mixtures thereof.
  • Powders and sprays can contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • the sprays can contain other customary propellants, such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons, such as butane and propane.
  • the "bond” means that the indicated substituent does not exist, and both end portions of the substituent are directly connected to form a bond.
  • Alkyl when taken as a group or part of a group is meant to include C1 - C20 straight or branched chain aliphatic hydrocarbon groups. Preferably it is a C 1 -C 10 alkyl group, more preferably a C 1 -C 6 alkyl group.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-di Methylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1 -Ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethyl Butyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl Wait. Alkyl groups can be substituted or unsubstituted.
  • Alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. Alkenyl groups can be optionally substituted or unsubstituted.
  • Alkynyl refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond, which may be straight or branched. Preferred are C2 - C10 alkynyl groups, more preferably C2 - C6 alkynyl groups, and most preferably C2 - C4 alkynyl groups. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the like. Alkynyl groups can be substituted or unsubstituted.
  • Cycloalkyl refers to saturated or partially saturated monocyclic, fused, bridged and spirocyclic carbocyclic rings. Preferably it is C 3 -C 12 cycloalkyl, more preferably C 3 -C 8 cycloalkyl, most preferably C 3 -C 6 cycloalkyl.
  • Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptyl Alkenyl, cyclooctyl, etc., preferably cyclopropyl and cyclohexenyl. Cycloalkyl groups can be optionally substituted or unsubstituted.
  • “Spirocycloalkyl” refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and the single rings share one carbon atom (called spiro atom) with each other, and the ring contains one or more aromatic systems with double bonds but none of the rings have fully conjugated pi electrons.
  • spiro atom carbon atom
  • it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • spirocycloalkyl groups are divided into mono-spiro, double-spiro or poly-spirocycloalkyl groups, preferably mono-spiro and double-spirocycloalkyl groups, preferably 4-membered/5-membered, 4-membered Yuan/6 Yuan, 5 Yuan/5 Yuan or 5 Yuan/6 Yuan.
  • spirocycloalkyl include, but are not limited to, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl.
  • “Fused cycloalkyl” refers to a 5- to 18-membered all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms with each other, one or more rings may contain one or more double bonds, But none of the rings have an aromatic system with fully conjugated pi electrons, preferably 6 to 12 membered, more preferably 7 to 10 membered. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicycloalkyl.
  • fused cycloalkyl include, but are not limited to: bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, Decalinyl or tetrahydrophenanthryl.
  • “Bridged cycloalkyl” refers to an all-carbon polycyclic group of 5 to 18 members, containing two or more cyclic structures, sharing two carbon atoms that are not directly connected to each other, and one or more rings may contain one or more Aromatic systems in which multiple double bonds, but none of the rings have fully conjugated pi electrons, are preferably 6 to 12 membered, more preferably 7 to 10 membered. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bridged cycloalkyl include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-dicyclo[3.2.1]octyl Cyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, (1r,5r)-bicyclo[3.3.2]decyl.
  • Heterocyclyl “heterocycle,” or “heterocyclic” are used interchangeably herein to refer to a non-aromatic heterocyclyl in which one or more of the ring-forming atoms is a heteroatom, such as oxygen, Nitrogen, sulfur atoms, etc., including monocyclic, fused, bridged and spiro rings. It preferably has a 5- to 7-membered monocyclic ring or a 7- to 10-membered bi- or tricyclic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulfur.
  • heterocyclyl examples include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxothiomorpholinyl, piperidinyl , 2-oxopiperidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and piperazinyl .
  • Heterocyclyl groups can be substituted or unsubstituted.
  • “Spiroheterocyclyl” refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and single rings share one atom with each other, and the ring contains one or more double bonds, but no An aromatic system with fully conjugated pi electrons in one ring, wherein one or more ring atoms are selected from nitrogen, oxygen, or a heteroatom of S(O) r (wherein r is selected from 0, 1, or 2), and the remaining ring atoms are carbon.
  • it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • Spirocycloalkyl groups are classified into mono-spiroheterocyclyl, bis-spiroheterocyclyl or poly-spiroheterocyclyl according to the number of spiro atoms shared between rings, preferably mono-spiroheterocyclyl and bis-spiroheterocyclyl. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocyclyl group.
  • spiroheterocyclyl include, but are not limited to: 1,7-dioxaspiro[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[4.4]nonyl Heterospiro[3.5]nonyl and 5-oxaspiro[2.4]heptyl.
  • “Fused heterocyclic group” refers to an all-carbon polycyclic group containing two or more ring structures sharing a pair of atoms with each other, one or more rings may contain one or more double bonds, but no ring has complete Conjugated pi-electron aromatic systems wherein one or more ring atoms are selected from nitrogen, oxygen or heteroatoms of S(O) r (wherein r is selected from 0, 1 or 2) and the remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic groups.
  • fused heterocyclyl include, but are not limited to: octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo[3.1. 0] Hexyl, octahydrobenzo[b][1,4]dioxine or
  • “Bridged heterocyclyl” refers to a 5- to 14-membered, 5- to 18-membered polycyclic group containing two or more cyclic structures that share two atoms that are not directly connected to each other, and one or more rings may be Aromatic systems containing one or more double bonds but none of the rings have fully conjugated pi electrons, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) r (wherein r is selected from 0, 1 or 2), the remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bridged heterocyclyl include, but are not limited to: 2-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.2]octyl, and 2-azabicyclo Cyclo[3.3.2]decyl.
  • Aryl refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be joined together in a fused fashion.
  • aryl includes monocyclic or bicyclic aryl groups such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferred aryl groups are C6 - C10 aryl groups, more preferred aryl groups are phenyl and naphthyl, and most preferred are naphthyl.
  • Aryl groups can be substituted or unsubstituted.
  • Heteroaryl refers to an aromatic 5 to 6 membered monocyclic or 8 to 10 membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur.
  • heteroaryl include but are not limited to furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiazolyl oxadiazolyl, benzodioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl,
  • Heteroaryl groups can be substituted or unsubstituted.
  • “Fused ring” refers to a polycyclic group in which two or more ring structures share a pair of atoms with each other, one or more rings may contain one or more double bonds, but at least one ring is not completely conjugated A pi-electron aromatic system, wherein the ring atoms are selected from 0, one or more heteroatoms selected from nitrogen, oxygen or S(O) r (wherein r is selected from 0, 1 or 2), and the remaining ring atoms are carbon .
  • the condensed ring preferably includes a bicyclic or tricyclic condensed ring, wherein the bicyclic condensed ring is preferably a condensed ring of an aryl group or a heteroaryl group and a monocyclic heterocyclic group or a monocyclic cycloalkyl group. Preferably it is 7 to 14 yuan, more preferably 8 to 10 yuan. Examples of "fused rings" include, but are not limited to:
  • Alkoxy refers to a group (alkyl-O-). Wherein, alkyl is as defined herein. Ci - C6 alkoxy groups are preferred. Examples include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, and the like.
  • Haloalkyl means a group in which an alkyl group is optionally further substituted with one or more halogens, wherein alkyl is as defined herein.
  • Hydroalkyl refers to a group in which an alkyl group is optionally further substituted with one or more hydroxy groups, wherein alkyl is as defined herein.
  • Methods refers to a group in which the methyl group is optionally further substituted with one or more hydroxy groups.
  • Haloalkoxy refers to a group in which the alkyl group of (alkyl-O-) is optionally further substituted with one or more halogens, wherein alkoxy is as defined herein.
  • Halogen refers to fluorine, chlorine, bromine and iodine.
  • Amino refers to -NH2 .
  • Cyano refers to -CN.
  • Niro refers to -NO2 .
  • Benzyl refers to -CH2 -phenyl.
  • Carboxyl refers to -C(O)OH.
  • Carboxylate means -C(O)O-alkyl or -C(O)O-cycloalkyl, wherein alkyl and cycloalkyl are as defined above.
  • DMSO dimethyl sulfoxide
  • BOC refers to t-butoxycarbonyl
  • Ts refers to p-toluenesulfonyl.
  • T3P refers to propylphosphoric anhydride.
  • DPPA diphenylphosphoryl azide
  • DEA diethylamine
  • X-PHOS Pd G2 refers to chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino- 1,1'-biphenyl)]palladium(II).
  • Pd(dppf)Cl2 refers to [1,1' - bis(diphenylphosphino)ferrocene]palladium dichloride.
  • Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of one another, are substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort. For example, amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
  • R 6 and R 7 together with the atoms to which they are attached form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) r , and the
  • R 8 , R 9 and R 10 are each independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclic group , aryl or heteroaryl are optionally further selected from one or more groups selected from hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl , substituted by a substituent of a carboxyl group or a carboxylate group;
  • r 0, 1 or 2.
  • the compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomeric forms. All stereoisomeric forms of the compounds of the present invention are contemplated, including but not limited to diastereomers, enantiomers, and atropisomers and geometric (conformational) isomers and Their mixtures, such as racemic mixtures, are within the scope of the present invention.
  • the structures depicted herein also include all isomeric (eg, diastereomeric, enantiomeric, and atropisomeric and geometric (conformational) isomeric forms of such structures; for example, , the R and S configuration of each asymmetric center, the (Z) and (E) double bond isomers, and the (Z) and (E) conformational isomers.
  • isomeric eg, diastereomeric, enantiomeric, and atropisomeric and geometric (conformational) isomeric forms of such structures; for example, , the R and S configuration of each asymmetric center, the (Z) and (E) double bond isomers, and the (Z) and (E) conformational isomers.
  • the individual stereoisomers of the compounds of the present invention as well as Enantiomeric mixtures, diastereomeric mixtures and geometric (conformational) isomer mixtures are all within the scope of the present invention.
  • “Pharmaceutically acceptable salts” refers to certain salts of the above-mentioned compounds that retain their original biological activity and are suitable for medicinal use.
  • the pharmaceutically acceptable salt of the compound represented by the formula (I) may be a metal salt or an amine salt with a suitable acid.
  • “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as physiologically pharmaceutically acceptable carriers and excipients Form.
  • the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
  • the preparation method of the compound described in the general formula (I) of the present invention or its stereoisomer, tautomer or its pharmaceutically acceptable salt comprises the following steps:
  • the compound of general formula (IA) and the compound of general formula (IB) are subjected to a Suzuki coupling reaction under the action of a palladium catalyst and a basic reagent to obtain a compound of general formula (IC); the compound of general formula (IC) is further deprotected, and any Select to further remove the protecting group on ring B to obtain the compound of general formula (I);
  • X is a leaving group, preferably chlorine
  • PG is a protecting group, preferably tert-butoxycarbonyl
  • M is selected from -B(OH) 2 , -BF 3 K or
  • Ring B, R 1 to R 4 , Q, Y, m and n are as defined in the general formula (I).
  • Mass spectrum is obtained by LC/MS instrument, and the ionization mode can be ESI or APCI.
  • the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the size of the silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm, and the size of the TLC separation and purification products is 0.4mm ⁇ 0.5mm.
  • CD3OD Deuterated methanol.
  • the compound was purified using column chromatography and thin layer chromatography eluent system, wherein the system was selected from: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: dichloromethane And ethyl acetate system, D: dichloromethane and ethanol system, wherein the volume ratio of the solvent varies according to the polarity of the compound, and a small amount of acidic or basic reagents can also be added for conditions, such as acetic acid or triethylamine.
  • 2,4,7-Trichloro-8-fluoropyrido[4,3-d]pyrimidine 1a (1.1 g, 4.36 mmol) was dissolved in dichloromethane (19.96 mL) and N,N-diisopropyl was added Ethylamine (3.94g, 30.50mmol, 5.04mL), cooled to -40°C, added (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1b (924.96 mg, 4.36 mmol) was reacted at room temperature for 1 hour.
  • Test Example 1 Determination of the Inhibitory Activity of the Compounds of the Invention on p-ERK1/2 in AGS Cells
  • the following method was used to determine the inhibitory activity of the compounds of the present invention on p-ERK1/2 in AGS cells.
  • This method uses the Advanced phospho-ERK1/2 (Thr202/tyr204) kit (Cat. No. 64AERPEH) from Cisbio Company.
  • Kit instructions for detailed experimental operation, please refer to the kit instructions.
  • AGS cells (containing KRAS G12D mutation) were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
  • AGS cells were cultured in F12K complete medium containing 10% fetal bovine serum, 100 U penicillin and 100 ⁇ g/mL streptomycin.
  • AGS cells were plated in 96-well plates at 40,000 cells per well, and the medium was complete medium, and cultured overnight in a 37° C., 5% CO2 incubator.
  • the test compound was dissolved in DMSO to prepare a 10mM stock solution, then diluted with F12K complete medium, and 100uL of F12K complete medium containing the corresponding concentration of the test compound was added to each well.
  • the final concentration range of the test compound in the reaction system After culturing in a cell incubator for 3 hours, discard the cell supernatant, wash the cells with ice-bathed PBS, and then add 50 ⁇ l of 1 ⁇ cell phospho/total protein lysis buffer (Advanced phospho-ERK1 /2 kit components) for lysis, the 96-well plate was placed on ice for half an hour, and then the lysate was detected according to the instructions of the Advanced phospho-ERK1/2 (Thr202/tyr204) kit.
  • 1 ⁇ cell phospho/total protein lysis buffer Advanced phospho-ERK1 /2 kit components
  • the ratio of fluorescence intensity of DMSO was compared, the percentage inhibition rate of the test compound at each concentration was calculated, and a nonlinear regression analysis was performed on the value-inhibition rate of the test compound concentration by GraphPad Prism 5 software to obtain the IC 50 value of the compound. .
  • the preferred compound of the present invention has obvious inhibitory effect on the activity of p-ERK1/2 in AGS cells, the preferred compound has an IC 50 ⁇ 500nM, and the more preferred compound has an IC 50 ⁇ 200nM.
  • Test Example 2 The compound of the present invention inhibits the proliferation of AsPC-1 cells
  • AsPC-1 metal pancreatic adenocarcinoma
  • AsPC-1 cells (containing KRAS G12D mutation) were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 U penicillin, 100 ⁇ g/mL streptomycin and 1 mM Sodium Pyruvate middle. cell viability through Assays were performed with the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).
  • test compound was first dissolved in DMSO to prepare a 10 mM stock solution, and then diluted with culture medium to prepare a test sample.
  • the final concentration of the compound was in the range of 1000nM-0.015nM .
  • Cells in logarithmic growth phase were seeded into 96-well cell culture plates at a density of 800 cells per well, cultured overnight at 37°C in a 5% CO2 incubator, followed by the addition of test compounds for 120 hours. After the incubation, 50uL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes.
  • the luminescence value of each well of the sample was read on a microplate reader using Luminescence mode.
  • the percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO), and then a nonlinear regression analysis was performed in the GraphPad Prism 5 software with the compound concentration logarithm-inhibition rate to obtain the compound inhibiting cell proliferation. the IC50 value.
  • the preferred compound of the present invention has obvious inhibitory effect on the proliferation of AsPC-1 cells, the preferred compound has an IC 50 ⁇ 500nM, and the more preferred compound has an IC 50 ⁇ 200nM.
  • Test Example 3 Determination of the inhibitory ability of the compounds of the present invention on the interaction between KRAS G12D and RAF1 protein
  • the following method was used to determine the ability of the compounds of the invention to block the KRAS G12D:RAF1 protein interaction under in vitro conditions.
  • This method uses the KRAS-G12C/SOS1 BINDING ASSAY KITS kit (63ADK000CB21PEG) from Cisbio Company, and the detailed experimental operation can be referred to the kit instructions.
  • the compound of the present invention has a good inhibitory ability on the interaction between KRAS G12D and RAF1 protein.
  • Test Example 4 Inhibitory assay of the compounds of the present invention on AGS cell proliferation
  • AGS human gastric adenocarcinoma
  • AGS cells (containing KRAS G12D mutation) were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in F-12K medium containing 10% fetal bovine serum, 100 U penicillin and 100 ⁇ g/mL streptomycin. cell viability through Assays were performed with the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).
  • test compound was first dissolved in DMSO to prepare a 10 mM stock solution, and then diluted with culture medium to prepare a test sample.
  • the final concentration of the compound was in the range of 1000nM-0.015nM .
  • Cells in logarithmic growth phase were seeded into 96-well cell culture plates at a density of 500 cells per well, cultured overnight at 37°C in a 5% CO2 incubator, followed by the addition of test compounds for 72 hours. After the incubation, 50uL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes.
  • the luminescence value of each well of the sample was read on a microplate reader using Luminescence mode.
  • the percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO), and then a nonlinear regression analysis was performed in the GraphPad Prism 5 software with the compound concentration logarithm-inhibition rate to obtain the compound inhibiting cell proliferation.
  • the IC50 values are shown in Table 2.
  • the compound of the present invention has a good inhibitory effect on the proliferation of AGS cells.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dérivé hétérocyclique, son procédé de préparation et son utilisation en médecine. En particulier, la présente invention concerne un dérivé hétérocyclique représenté par la formule générale (I), son procédé de préparation et un sel pharmaceutiquement acceptable de celui-ci, ainsi que leur utilisation en tant qu'agents thérapeutiques, en particulier en tant qu'inhibiteurs de G12D KRas, la définition des substituants dans la formule générale (I) étant la même que celle dans la description.
PCT/CN2022/083615 2021-04-28 2022-03-29 Dérivé hétérocyclique, son procédé de préparation et son utilisation WO2022227987A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280006427.5A CN116157401A (zh) 2021-04-28 2022-03-29 杂环类衍生物及其制备方法和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110465356.2 2021-04-28
CN202110465356 2021-04-28
CN202110631110 2021-06-07
CN202110631110.8 2021-06-07

Publications (1)

Publication Number Publication Date
WO2022227987A1 true WO2022227987A1 (fr) 2022-11-03

Family

ID=83846632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/083615 WO2022227987A1 (fr) 2021-04-28 2022-03-29 Dérivé hétérocyclique, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN116157401A (fr)
WO (1) WO2022227987A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (fr) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
WO2021041671A1 (fr) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (fr) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
WO2021041671A1 (fr) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG XIAOLUN, ALLEN SHELLEY, BLAKE JAMES F., BOWCUT VICKIE, BRIERE DAVID M., CALINISAN ANDREW, DAHLKE JOSHUA R., FELL JAY B., FISC: "Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 4, 24 February 2022 (2022-02-24), US , pages 3123 - 3133, XP055952002, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01688 *

Also Published As

Publication number Publication date
CN116157401A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
JP7394074B2 (ja) 治療用化合物
WO2022206723A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation en médecine
KR102236605B1 (ko) 피리도피리미딘온 cdk2/4/6 억제제
WO2023025116A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation en médecine
WO2022135432A1 (fr) Composés hétérocycliques macrocycliques utilisés en tant qu'inhibiteurs d'egfr et leur utilisation
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
WO2016011979A1 (fr) Dérivé 7h-pyrrolo[2,3-d]pyrimidine 2,4-disubstituté, procédé de préparation et utilisation médicinale de ce dernier
WO2022037631A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2023001229A1 (fr) Dérivé pyrimidocyclique, son procédé de préparation et son utilisation
KR20210103973A (ko) 단백질 키나아제 분해 유도 화합물 및 이의 용도
WO2022037630A1 (fr) Dérivé tétracylique, procédé de préparation de celui-ci et son utilisation en médecine
CN116162099A (zh) 杂环类衍生物及其制备方法和用途
CN113929681A (zh) 四环类衍生物及其制备方法和用途
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN115557949A (zh) 四环类衍生物、其制备方法及其在医药上的应用
TW202341987A (zh) 一種Polθ抑制劑
CN116390923A (zh) 杂环类衍生物及其制备方法和用途
WO2022227987A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
JP7216105B2 (ja) Ｅｒｋキナーゼ阻害活性を有する化合物及びその使用
WO2022206724A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation
WO2022198905A1 (fr) Dérivé tricyclique, son procédé de préparation et son utilisation
WO2022199170A1 (fr) Dérivé tétracyclique, son procédé de préparation et son utilisation médicale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22794460

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22794460

Country of ref document: EP

Kind code of ref document: A1